Luminex Corporation (LMNX) : Wall Street Access Asset Management reduced its stake in Luminex Corporation by 0.45% during the most recent quarter end. The investment management company now holds a total of 244,019 shares of Luminex Corporation which is valued at $4,875,500 after selling 1,100 shares in Luminex Corporation , the firm said in a disclosure report filed with the SEC on May 2, 2016.Luminex Corporation makes up approximately 2.73% of Wall Street Access Asset Management’s portfolio.
Luminex Corporation closed down -0.36 points or -1.77% at $19.98 with 3,20,797 shares getting traded on Friday. Post opening the session at $20.18, the shares hit an intraday low of $19.86 and an intraday high of $20.4 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Aperio Group boosted its stake in LMNX in the latest quarter, The investment management firm added 3,499 additional shares and now holds a total of 13,048 shares of Luminex Corporation which is valued at $262,265. Quadrant Capital Group added LMNX to its portfolio by purchasing 43 company shares during the most recent quarter which is valued at $864.
On the company’s financial health, Luminex Corporation reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on May 2, 2016. Analyst had a consensus of $0.16. The company had revenue of $63.00 million for the quarter, compared to analysts expectations of $60.98 million. The company’s revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.23 EPS.
Luminex Corporation is a developer manufacturer and marketer of biological testing technologies with applications throughout the clinical diagnostic and life science industries. The Companys xMAP (Multi-Analyte Profiling) technology is being used within fields of drug discovery and development and for clinical diagnostics genetic analysis bio-defense food safety and biomedical research. In addition to its xMAP technology the Company has its MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The instruments in the Companys xMAP line include LX200 system which offers 100-plex testing; FLEXMAP 3D system which is a 500-plex testing system; and MAGPIX system which provides 50-plex testing at a lower cost using imaging rather than flow cytometry. The Companys products include Instruments Consumables Software and Assay Product Families.